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ABSTRACT Cervicovaginal mucus (CVM) can provide a barrier that precludes HIV and other sexually transmitted virions
from reaching target cells in the vaginal epithelium, thereby preventing or reducing infections. However, the barrier prop-
erties of CVM differ from woman to woman, and the causes of these variations are not yet well understood. Using high-
resolution particle tracking of fluorescent HIV-1 pseudoviruses, we found that neither pH nor Nugent scores nor total lac-
tic acid levels correlated significantly with virus trapping in unmodified CVM from diverse donors. Surprisingly, HIV-1
was generally trapped in CVM with relatively high concentrations of D-lactic acid and a Lactobacillus crispatus-dominant
microbiota. In contrast, a substantial fraction of HIV-1 virions diffused rapidly through CVM with low concentrations of
D-lactic acid that had a Lactobacillus iners-dominant microbiota or significant amounts of Gardnerella vaginalis, a bacte-
rium associated with bacterial vaginosis. Our results demonstrate that the vaginal microbiota, including specific species of
Lactobacillus, can alter the diffusional barrier properties of CVM against HIV and likely other sexually transmitted viruses
and that these microbiota-associated changes may account in part for the elevated risks of HIV acquisition linked to bacte-
rial vaginosis or intermediate vaginal microbiota.
IMPORTANCE Variations in the vaginal microbiota, especially shifts away from Lactobacillus-dominant microbiota, are associ-
ated with differential risks of acquiring HIV or other sexually transmitted infections. However, emerging evidence suggests that
Lactobacillus iners frequently colonizes women with recurring bacterial vaginosis, raising the possibility that L. iners may not be
as protective as other Lactobacillus species. Our study was designed to improve understanding of how the cervicovaginal mucus
barrier against HIV may vary between women along with the vaginal microbiota and led to the finding that the vaginal microbi-
ota, including specific species of Lactobacillus, can directly alter the diffusional barrier properties of cervicovaginal mucus. This
work advances our understanding of the complex barrier properties of mucus and highlights the differential protective ability of
different species of Lactobacillus, with Lactobacillus crispatus and possibly other species playing a key role in protection against
HIV and other sexually transmitted infections. These findings could lead to the development of novel strategies to protect
women against HIV.
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The vaginal epithelium produces little to no secreted mucins;instead, mucus coating the female reproductive tract is pri-
marily derived from mucin-secreting glands in the cervix (1). Cer-
vical mucus flows by gravitational and/or abdominal pressure
through the cervical os into the vaginal canal (2, 3), where it is
modified by fluid and ion exchange (4, 5), shed epithelial cells, and
the vaginal microbiota (6, 7). Thus, mucus secretions coating the
vaginal epithelium are frequently referred to as cervicovaginal
mucus (CVM) to emphasize both its origin and the unique phys-
icochemical properties that differentiate CVM from cervical mu-
cus. CVM is critical to reproductive health not only as a lubricant
that minimizes physical trauma to the underlying epithelium dur-
ing coitus but also by serving as the first line of defense against
transmission of infectious virions.
Vaginal microbes (8) can modify CVM biochemically to an
extent not yet fully understood (6). Until recently, the primary
method for characterizing the vaginal microbiota was Nugent
scoring, a morphology-based evaluation of the abundance of rod-
shaped, Gram-positive Lactobacillus spp. (the most prevalent bac-
teria in the vagina) and Gram-variable polymicrobial communi-
ties (7). Advances in high-throughput-sequencing technology
based on analysis of the 16S rRNA gene now afford high-
resolution culture-independent molecular methods that reveal
the full diversity of Lactobacillus spp. and other commensal or
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pathogenic microbes present in the vaginal microbiota, as well as
the dynamic nature of shifts between different microbial commu-
nities over short temporal scales (8, 9). Among the four most
common Lactobacillus species (L. crispatus, L. iners, L. jensenii, and
L. gasseri), an L. crispatus-dominant microbiota is found in about
14% of African-American women and over 45% of Caucasian
women, while an L. iners-dominant microbiota and a microbiota
comprising Gardnerella vaginalis and other bacteria associated
with bacterial vaginosis (BV) (10) are found in 36% and 40%,
respectively, of African-American women and in 27% and 10%,
respectively, of Caucasian women (8).
For vaginal transmission to occur, HIV must penetrate CVM
to reach target cells in the vaginal epithelium (or penile epithe-
lium, in the case of female-to-male transmission). CVM that ei-
ther retards or immobilizes HIV virions can directly reduce the
effective viral load that arrives at target cells and can potentially
prevent initial infections altogether. In prior work, we measured
the mobility of HIV in fresh human CVM and found that native
CVM from a limited number of college students, the majority with
vaginal microbiota likely dominated by L. crispatus, effectively
trapped HIV-1 virions (11). A follow-up study on a different pop-
ulation of women by a coauthor of that initial work reported that
CVM generally failed to trap HIV-1 virions (12). Since there are
substantial variations in the vaginal microbiota between women
and within the same woman over time (8, 9), differences in the
vaginal microbiota between the subject populations may well ac-
count for the reported differences between the two studies. Thus,
we sought to explore whether the vaginal microbiota, including
different strains of Lactobacillus spp., can alter the diffusional bar-
rier properties of CVM against HIV.
RESULTS
CVM with high D-lactic acid (D-LA) concentrations consis-
tently traps HIV-1. To reconcile the contrasting observations of
HIV mobility in CVM reported in the two previous publications,
we screened a larger subject pool than was included in our original
study and observed significant variation in the mobility of HIV-1
virus-like particles (pseudotyped with a YU2 envelope) in fresh,
minimally modified CVM that could be broadly divided into 2
categories (see, e.g., Movies S1 and S2 in the supplemental mate-
rial): CVM that traps the vast majority of HIV-1 virions (n  17 of
31 women) and CVM with a substantial population of rapidly
diffusing HIV-1 virions (n  14 of 31). On average, the mobile
fraction of HIV-1 was only 1.3%  0.6% in CVM samples that
trapped HIV-1 compared to 45%  8% in CVM samples with a
substantial fast-moving population (see Table S1), and the aver-
age effective diffusion coefficient (Deff) of HIV-1 in CVM with
substantial fast-moving viral populations was ~20-fold greater
than in CVM that effectively trapped HIV-1. In CVM samples that
trapped HIV-1, virions were trapped immediately after addition
into mucus and remained trapped for over more than 1 h of incu-
bation; similarly, in samples that failed to trap HIV-1, virions
remained diffusive even after extended incubation.
To begin to understand what might contribute to these varia-
tions in the diffusional barrier properties of CVM samples against
HIV, we first attempted to correlate the observed HIV-1 mobility
with three traditionally measured properties of CVM: pH, Nugent
score, and lactic acid (LA) content (Fig. 1). Although CVM gen-
erally did not trap HIV-1 at high vaginal pH, lower vaginal pH
(pH  4.2) was not predictive of HIV-1 trapping (Fig. 1B and E;
note that a pH level of 4.2 is the upper limit of CVM pH measured
under physiologically hypoxic conditions for women with what is
thought to be a clinically “normal” microbiota [13], while the
clinical criterion of a pH level of 4.5 for BV is based on measure-
ments in ambient air). Over 25% of the CVM specimens with a pH
level of 4.2 failed to trap HIV-1, and the average pH of CVM
samples that trapped HIV-1 (pH 3.99  0.04) was not statistically
different from that of samples that failed to trap HIV-1 (pH 4.03 
0.03) (see Fig. S1A and Table S1 in the supplemental material).
HIV-1 mobility also tended to be greater with higher Nugent
scores (see Fig. S1B), which is not surprising given the correlation
between BV and greater risk for HIV transmission (14, 15). How-
ever, nearly a third of the CVM samples that exhibited low Nugent
scores in the “normal” range (0 to 3 [7]) failed to trap HIV-1
(Fig. 1C and F), and the difference between low-Nugent-score
samples that trapped HIV-1 and those that did not trap HIV-1 was
not significant (average Nugent score of 1.07  0.30 versus 1.67 
0.49; see Fig. S1B). Likewise, high levels of total LA were not pre-
dictive of HIV-1 trapping in CVM (Fig. 1D and G), with average
LA levels of 0.96  0.09% (wt/vol) versus 0.85  0.07% (wt/vol)
for samples that trapped or did not trap HIV-1 among those with
“normal” LA levels (at least 0.7% [wt/vol] LA [13]) (see Fig. S1C).
We thus decided to seek other biomarkers that could more accu-
rately predict the barrier properties of CVM against HIV.
Humans can secrete only L-LA, which does not contribute sub-
stantially to the total LA found in the vagina (6). In contrast,
Lactobacillus spp. can produce both D-LA and L-LA, and different
species of Lactobacillus may differ in D-LA versus L-LA produc-
tion (6, 16, 17). Therefore, we tested whether D-LA or L-LA con-
tent might help reveal differences in the barrier properties of
CVM. We found that CVM samples that trapped HIV-1 at native
pH levels generally possessed substantial quantities of D-LA
(Fig. 2A and D); in contrast, CVM that failed to trap HIV-1 gen-
erally possessed significantly lower levels of D-LA. Among sam-
ples with relatively high levels of D-LA (0.3% [wt/vol]), 10 of 11
samples trapped HIV-1, with an average D-LA level of 0.52% 
0.07% (see Fig. S1D in the supplemental material). While the lone
sample that did not trap HIV-1 had a D-LA level of 0.39%, this
sample also had a Nugent score of 6 (in the “intermediate” range
bordering on bacterial vaginosis [7]). HIV-1 trapping in CVM did
not correlate with either the L-LA level or the D:L ratio (Fig. 2B
and E or C and F, respectively), and average differences in the
L-LA or D:L ratio between samples that trapped versus those that
did not trap HIV-1 were not statistically significant (see Fig. S1E
and F).
Given that the presence of high levels of D-LA appears to be an
effective predictor of HIV-1 trapping in CVM, we sought to eval-
uate whether D-LA directly mediates HIV trapping by adding
D-LA to CVM specimens with low endogenous D-LA levels. The
addition of D-LA to reach a final concentration in excess of 1%
(wt/vol) did not increase HIV-1 trapping in CVM (data not
shown), suggesting that D-LA is likely simply a surrogate indicator
of the diffusional barrier properties of CVM against HIV rather
than directly participating in interactions between HIV and mu-
cins.
The specific composition of the vaginal microbiota deter-
mines CVM barrier properties against HIV. Unlike humans, a
variety of bacteria can produce D-LA, with the majority of vaginal
D-LA presumably produced by commensal Lactobacillus spp., as
other bacteria such as Atopobium spp. produce relatively little lac-
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tic acid (6, 9). Thus, we speculated that differences in D-LA levels
between CVM specimens likely reflect the presence of different
species of Lactobacillus. RNA sequencing (RNAseq) analysis has
shown that L. crispatus generally expresses high levels of both D-
and L-lactate dehydrogenase leading to high levels of both D-LA
and L-LA, whereas many strains of L. iners exhibit reduced expres-
sion of D-lactate dehydrogenase relative to L-lactate dehydroge-
nase, resulting in low levels of D-LA but not of L-LA (17). We thus
hypothesized that the correlation between HIV mobility and the
level of D-LA in CVM likely reflects distinct microbial communi-
ties present in CVM. Using 16S rRNA gene sequencing, we char-
acterized the microbial composition and structure of a subset of
CVM specimens from our studies described above (Fig. 3A), and
we indeed found that CVM samples with high D-LA levels that
trapped HIV generally possessed an L. crispatus-dominant micro-
biota (group 1), whereas the majority of CVM that failed to trap
HIV possessed either an L. iners-dominant microbiota (group 2)
or significant quantities of G. vaginalis (group 3) (Fig. 3B). Group
1 CVM samples also had significantly lower pH and Nugent scores
and higher total and D-LA levels than other samples (Fig. 3C).
HIV-mucin interactions may be mediated by carboxyl
groups present on the surface of HIV virions. To begin to under-
stand mechanistically how HIV is trapped in CVM, we first inves-
tigated whether HIV-1 virions were trapped due to steric obstruc-
tion from the dense mucin mesh or due to adhesive interactions
with mucus constituents. We had previously measured the aver-
age mesh spacing in CVM to be ~340 nm, with over 80% of spac-
ings larger than 200 nm (18). This suggests that the majority of
HIV-1 virions (diameter, ~100 nm) should not be slowed appre-
ciably by steric obstruction, although it was unclear whether the
pore size of CVM could be substantially reduced by specific vagi-
nal microbes. To test this, we prepared polymeric nanoparticles
(diameter, ~200 nm) coated with polyethylene glycol (PEG) to
produce a mucoinert surface that prevents adhesive interactions
with mucins, whereby the diffusion of the beads is limited only by
FIG 1 (A) Representative traces of mobile versus trapped HIV-1 virions compared to PS-PEG nanoparticles that are mucoinert and readily diffuse through
CVM and compared to PS-COOH nanoparticles that are mucoadhesive and trapped in CVM. (B to G) HIV-1 mobility measured by average effective diffusivity
(Deff) (B to D) values or fraction of mobile virions (E to G) versus pH (B and E), Nugent score (C and F), or total LA (D and G) for n  31 CVM samples with
a pH level of 4.2 (n  12) or 4.2 (n  19). Dashed lines indicate the cutoff between samples with a significant mobile HIV-1 population (10% mobile) and
those in which HIV-1 is largely trapped (10% mobile). w/v, weight/volume.
FIG 2 HIV-1 mobility measured by average effective diffusivity (Deff) (A to
C) values or fraction of mobile virions (D to F) versus D-LA (A and D), L-LA
(B and E), or D:L ratio (C and F) for n  31 CVM samples with a pH level of
4.2 (n  12) or 4.2 (n  19). Dashed lines indicate the cutoff between
samples with a significant mobile HIV-1 population (10% mobile) and those
in which HIV-1 is largely trapped (10% mobile).
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physical obstruction from the mucus mesh. In this study, all CVM
specimens that trapped HIV-1 failed to trap the larger PEG-coated
beads (Fig. 4A; see also S2A and E in the supplemental material).
This confirms that HIV-1 was trapped by adhesive interactions
with mucus constituents.
We next sought to determine whether the adhesive interac-
tions that facilitate HIV trapping are specific to HIV-1 by investi-
gating whether the interactions involve trimeric gp120/gp41 Env
spikes. To do so, we prepared Env mCherry-Gag-tagged pseu-
doviruses (i.e., without the HIV-specific envelope glycoprotein)
and compared their mobility in the same CVM specimens to that
of virions with intact envelope glycoprotein. We found that the
Env pseudoviruses exhibited comparable trapping in CVM with
high D-LA content as well as similar mobile fractions in CVM with
low D-LA content (Fig. 4B; see also Fig. S2B and F in the supple-
mental material). This indicates that the adhesive interactions re-
sponsible for trapping HIV-1 viruses in CVM do not involve HIV-
specific viral proteins and may instead be based on interactions
between mucins and components of the lipid membrane of the
viruses.
Mucins, due to their dense glycosylation, contain many car-
boxyl groups that are negatively charged at neutral pH (i.e.,
COO) but that become increasingly neutral as pH decreases and
COO groups are protonated (i.e., COOH). Similarly, the sur-
faces of HIV and other enveloped viruses also contain a high den-
sity of carboxyl groups derived from either glycans on viral pro-
teins or, more generally, human glycoproteins and glycolipids
naturally incorporated into the viral membrane. Protonation of
carboxyl groups both on the virus surface and on mucins may
FIG 3 (A) 16S rRNA sequencing and RNAseq analysis of CVM specimens reveals groups with distinct vaginal microbiotas: L. crispatus-dominant microbiota
(group 1), L. iners-dominant microbiota (group 2), and microbiota containing a significant fraction of G. vaginalis (group 3). The color bar indicates the
abundance of different bacterial species as a proportion of all species in the sample. Annulus charts depict the average distributions of the bacterial population
across species of lactobacilli, Gardnerella vaginalis, and other species within each group. Donor identification numbers (IDs) are indicated to allow comparisons
to the biochemical characterization data and bacterial abundance values in Tables S1 and S2 in the supplemental material. (B) HIV-1 mobility measured by
average effective diffusivity (Deff) values or fraction of mobile virions in CVM samples within each group. The dashed line indicates the cutoff between samples
with a significant mobile HIV-1 population (10% mobile) and those in which HIV-1 is largely trapped (10% mobile). (C) Average pH, Nugent score, total
LA, D-LA, L-LA, and D:L ratio for CVM samples within each group. *, P  0.05 (statistically significant difference between group 1 and groups 2 and 3).
FIG 4 Comparison of average effective diffusivity (Deff) values for mucoinert
synthetic beads (PS-PEG) (A), HIV-1 Env pseudovirus (B), or PS-COOH
(C) to that of HIV-1 in native CVM. Data represent n  8, 13, and 8 distinct
CVM samples for PS-PEG, HIV-1 Env, and PS-COOH, respectively. Lines
connect pairs of data points for the same sample.
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supply the protons necessary to form hydrogen bonds, and the
extent of such hydrogen bonding increases as mucus pH decreases
to approach the pKa of the carboxyl groups (~3 [19]). Thus, we
speculated that virions in native, acidic CVM samples that trap
HIV-1 may be immobilized via multiple hydrogen bonds between
surface carboxyl groups and mucins and that protonation of even
a small fraction of carboxyl groups may be adequate to create
sufficient hydrogen bonds to stop the diffusion of viruses through
mucus. To test this hypothesis, we measured the mobility of
carboxyl-modified latex beads (polystyrene [PS]-COOH) in a
subset of CVM specimens. As we expected, PS-COOH was mostly
trapped in CVM specimens in which the HIV-1 virions were
largely trapped and displayed substantial mobility in CVM speci-
mens that failed to trap HIV-1 (Fig. 4C; see also Fig. S2C and G in
the supplemental material). We further found that neutralizing
CVM, which eliminates essentially all protonated carboxyl
groups, reduced the adhesive interactions between HIV-1 and
mucus constituents (Fig. 5; see also Fig. S2D and H). Since Env
pseudoviruses that lack viral glycoproteins on the viral surface also
exhibited diffusion kinetics similar to those of pseudoviruses with
Env, it is likely that the bulk of the interactions between the viral
surface and mucins are via carboxyls on host-derived envelope
glycolipids or glycoproteins rather than via carboxyls on viral gly-
coproteins.
DISCUSSION
Although CVM is densely populated by vaginal microbes, the re-
lationship between the vaginal microbiota and the barrier prop-
erties of CVM remains poorly understood. The primary associa-
tion between mucus and HIV transmission is typically in the
elevated risks for women with episodes of BV of acquiring HIV
and various other sexually transmitted infections (STI). BV is
commonly diagnosed in research settings by Nugent scoring or in
clinical settings by Amsel’s criteria (20), which include an elevated
pH (4.5) and increased watery vaginal discharge. It is thought
that watery vaginal fluid allows HIV to more easily reach target
cells in the vaginal epithelium (21), resulting in a greater risk of
transmission. Consistent with this notion, we found that CVM
with substantial (i.e., 5%) quantities of G. vaginalis, a bacterium
frequently associated with BV, failed to trap HIV-1. Surprisingly,
we discovered that even differences in specific Lactobacillus spp.
can directly impact the barrier properties of CVM: CVM from
women with an L. crispatus-dominant microbiota consistently
trapped HIV-1, whereas CVM from women with an L. iners-dom-
inant microbiota mostly failed to do so. Importantly, CVM that
trapped HIV-1 virions also trapped Env pseudoviruses and
carboxyl-modified latex beads, suggesting that CVM with
L. crispatus-dominant microbiota may broadly preclude the pen-
etration of HIV across different clades/strains as well as that of
other enveloped viruses transmitted sexually.
Previously, Lactobacillus spp. were thought to be associated
with only a moderate reduction in the risks of acquiring HIV and
other STIs. Indeed, epidemiological studies suggest that the risk
for women with intermediate microbiota or BV of acquiring HIV
or other STIs is only ~2-fold to 4-fold higher than the risk for
women with Lactobacillus-dominant microbiota. Unfortunately,
the common method of categorizing the vaginal microbiota in
these studies, Nugent scoring (7), does not differentiate between
different species of Lactobacillus or account for the potentially
rapidly fluctuating nature of the vaginal microbiota (Nugent scor-
ing is typically performed only at the onset of a clinical trial rather
than throughout the trial, while episodes of BV may last only a few
days at a time [22, 23]). Recent evidence has shown that L. iners is
commonly found in women who have had episodes of BV or in-
termediate microbiota (23). It is thus very likely that a significant
population of women with an L. iners-dominant microbiota that
frequently shifts to an intermediate microbiota or BV may have
been included in the “healthy” protective vaginal microbiota
group in prior epidemiological studies. This, in turn, suggests that
the risks of acquiring STIs when a woman possesses an L. crispa-
tus-dominant microbiota (and, potentially, other Lactobacillus
spp. besides L. iners) are likely markedly lower than previously
estimated. If true, this implies that methods ensuring an L. crispa-
tus-dominant microbiota may be among the most effective means
of reducing vaginal HIV transmission.
We posit that L. crispatus may mediate vaginal protection
against HIV by at least three mechanisms: (i) enhanced trapping
of viruses via hydrogen bonding to mucins at low pH, (ii) direct
inactivation of cell-free or cell-associated HIV through secreted
lactic acid (24), and (iii) inhibition of other bacteria that could
compromise CVM barrier properties and thereby elevate risks for
HIV acquisition. First, lactic acid continuously secreted by Lacto-
bacillus spp. creates an acidic environment in the range of pH 3.5
to 4 under anaerobic conditions (13, 25). Numerous studies have
shown that L. crispatus produces not only more D-LA but also
more total LA than L. iners, with correspondingly lower pH
(Fig. 3C) (8, 17). Lower pH, in turn, promotes hydrogen bonding
among carboxylic acid groups, which our studies suggest likely
play a role in interactions between the virus surface and mucins.
Greater LA secretion may also lead to more-rapid restoration of
the native acidic environment upon exposure to semen. Second,
in addition to serving as a marker of the diffusional barrier prop-
erties of CVM, there is emerging evidence that LA may facilitate
protection by other mechanisms. For example, LA acidification
can rapidly inactivate sperm as well as prevent vaginal coloniza-
tion by nonindigenous organisms (16, 25–28). Recent evidence
suggests that LA possesses increased antimicrobial activity beyond
acidity alone (11, 24, 25), and Aldunate et al. showed that vaginal
concentrations of LA can potently inactivate HIV (24). Further-
more, low (5.8) pH quickly immobilizes and kills human leuko-
cytes (29), which, combined with the CVM diffusional barrier
surrounding the cells, is likely to effectively inhibit any cell-
associated transmission of HIV via immune cells present in the
mucus layer. Finally, cultivation-based studies have shown that
women with vaginal microbiota colonized by L. crispatus have a
lower risk of BV acquisition than women colonized by other spe-
FIG 5 Comparison of average effective diffusivity values for HIV-1 in native
versus neutralized (pH 7) CVM. Data represent n  31 distinct CVM samples.
Lines connect pairs of data points for the same sample.
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cies of lactobacilli (30). Lactic acid at low (4.5) pH is a potent
bactericide against BV-associated bacteria (25), and L. crispatus
may also produce bacteriocins that ward off other bacteria, in-
cluding L. iners and G. vaginalis (31). G. vaginalis can secrete high
levels of sialidases and other mucin-degrading enzymes (21, 32),
and it is possible that some strains of L. iners may also secrete
enzymes that reduce HIV trapping in CVM, either by destroying
the mucin network that holds adhered viruses in place or by cleav-
ing binding groups on mucins that HIV virions bind to in
L. crispatus-dominant CVM. The various extents to which HIV
and carboxyl-modified latex beads were trapped in native CVM
may thus reflect various concentrations of bacterial enzymes in
CVM, which in turn would impact the extent to which mucins are
altered biochemically. Once mucins are degraded, their ability to
trap HIV is likely irreversibly compromised. Thus, addition of
exogenous D-LA did not enhance trapping, and we speculate that
addition of L. crispatus to ex vivo CVM also would not facilitate
trapping. In contrast to L. crispatus, L. iners does not appear to
produce bacteriocins (33), which may contribute to a higher fre-
quency of shifts to intermediate or BV microbiota. In general, the
presence of L. iners has been found to correlate with vaginal met-
abolic profiles that are intermediate with respect to those corre-
lated with BV-associated bacteria and L. crispatus (34), although
such studies have yet to reveal additional metabolite differences
specifically attributable to L. iners versus L. crispatus. (Note that
while L. crispatus is thought to be a hydrogen peroxide producer
and L. iners a nonproducer [35], this difference is unlikely to be
relevant in vivo, since hydrogen peroxide production requires aer-
obic conditions and the vagina is typically hypoxic [13].) The
combination of the factors discussed above may explain why no
single CVM characteristic measured in this study—pH, Nugent
scores, total lactic acid, or even D-LA— correlated as strongly with
HIV mobility as did the vaginal microbiota.
CVM can exhibit markedly different macroscopic characteris-
tics (e.g., color and consistency) over time as well as between
women. Nevertheless, it is important to note that the physical
properties of the local environment (i.e., at the length scale of HIV
virions) that enable or block HIV diffusional mobility in CVM are
distinct from the macroscopic physical properties of the mucus gel
(36, 37). For example, in our previous study (11), as well as the
current work, the bulk viscoelasticities of CVM did not appear to
differ between the CVM specimens that trapped HIV and those
that failed to trap HIV, including those with substantial quantities
of G. vaginalis. Likewise, variations in the macroscopic properties
of CVM do not necessarily compromise its ability to serve as an
effective and consistent diffusional barrier against HIV and other
STIs. Consequently, the key to harnessing CVM as a protective
barrier is to better understand the complex molecular and bio-
physical interactions that occur within CVM, and our current
effort to link vaginal microbial communities to HIV mobility in
CVM provides important first clues as to how the innate diffu-
sional barrier properties of CVM may be reinforced against STIs.
Trapping or even slowing viruses in mucus is likely an effective
mechanism of mucosal protection that operates not only by re-
ducing the viral load arriving at target cells and purging trapped
viruses by natural mucus clearance mechanisms but also by in-
creasing the likelihood of inactivation via other innate protective
mechanisms (e.g., defensins, thermal inactivation, etc. [38, 39])
while virus penetration of mucus is delayed. The potential effec-
tiveness of trapping in mucus is perhaps best exemplified by stud-
ies in reproductive biology: sperm trapped in mucus by antisperm
antibodies are excluded from contacting target cells (i.e., eggs),
and the inability of sperm to penetrate mucus correlates strongly
with infertility (40). Recently, we showed that mucosal IgG against
herpes simplex virus (HSV-1) can trap HSV-1 in CVM at subneu-
tralizing concentrations and that even a nonneutralizing IgG can
block vaginal Herpes transmission in mice by trapping viruses in
mucus (41). (Note that while it is also possible for HIV to be
trapped by HIV-binding IgG, this mechanism is unlikely to have
played a role in the current study, since samples were obtained
from individuals who self-reported as HIV negative.) Our current
finding that L. crispatus can enhance the diffusional barrier prop-
erties of native CVM adds to emerging insights into the mecha-
nisms of both innate and adaptive vaginal mucosal immune pro-
tection based on trapping viruses in mucus.
It is important to note that our discoveries have been made
possible only by investigation of pathogen mobility in fresh, min-
imally modified CVM collected from a relatively large number of
women. Few prior studies of mucosal protection have been per-
formed with human mucus secretions ex vivo, since fresh mucus
gel is more difficult to obtain and handle than diluted fluids from
lavages or swabs or from mucins isolated from cell cultures. We
anticipate that investigating the effect of exposure to semen will
also be critical to fully understanding CVM barrier functions in
vivo. Semen contains degradative enzymes that may alter mucins
and/or the HIV surface (42). In addition, HIV transmitted from
ejaculate to CVM may be coated with proteins or other semen
components that affect HIV diffusion in CVM. Perhaps most im-
portantly, semen transiently dilutes and neutralizes CVM (the en-
tire vagina becomes acidic again within minutes to hours, depend-
ing on the rate of postcoital discharge of semen [43]), which can
interfere with its ability to block HIV. Nevertheless, semen is un-
likely to fully mix with mucus, and there is likely to be a pH gra-
dient within the mucus layer that is more acidic closer to the
epithelium, where lactobacilli are most abundant. Further studies
using fresh ex vivo semen and mucus gels from women with di-
verse microbiota, and in greater numbers of samples, will afford a
better understanding of the barrier properties of physiological
mucus secretions and will likely lead to the development of novel
approaches to reinforce the mucosal barrier against pathogens.
MATERIALS AND METHODS
Preparation of fluorescent HIV-1 and Env pseudoviruses.
Replication-defective HIV-1, internally labeled with an mCherry-Gag
construct to avoid alteration of the viral surface, was prepared by trans-
fection of 293T cells with plasmids encoding NL4-3LucVprEnv, Gag-
mCherry, and YU2 Env in a 4:1:1 ratio. The cell supernatant was collected
48 h later, and fluorescently tagged virions from the cell supernatant were
purified by centrifugation through 25% sucrose at 160,000 	 g for 2.5 h.
The virions were then washed, resuspended in phosphate-buffered saline
(PBS), divided into aliquots, and stored at 80°C. Env pseudoviruses
were similarly prepared without incorporating the Env plasmid.
Nanoparticle preparation and characterization. Fluorescent,
carboxyl-modified latex beads (PS-COOH) (200 nm in diameter) were
purchased from Molecular Probes (Eugene, OR). These particles feature a
high surface density of COOH groups (~7 to 8 COOH/nm2) and a nega-
tively charged surface at neutral pH (49.3  2.1 mV). Mucoinert nano-
particles (PS-PEG) were prepared by conjugating 2 kDa of amine-
modified polyethylene glycol (PEG; Rapp Polymere, Tuebingen,
Germany) to PS-COOH particles via a carboxyl-amine reaction, as pub-
lished previously (44). PEG conjugation was confirmed by a near-neutral
-potential (3.23  0.32 mV), measured in 10 mM NaCl solution
Nunn et al.
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(pH 7) using a Zetasizer Nano ZS90 system (Malvern Instruments, South-
borough, MA).
CVM collection and characterization. Cervicovaginal mucus (CVM)
collection was performed as published previously (11, 18, 44). Briefly,
undiluted CVM secretions, averaging 0.3 g per sample, were obtained
from 31 women (one sample per participant) of reproductive age ranging
from 19 to 33 years of age (mean  standard error of the mean [SEM],
24.5  0.7 years) by using a self-sampling menstrual collection device
(Instead Softcup) following a protocol approved by the Institutional Re-
view Board of the University of North Carolina at Chapel Hill. Informed
consent of participants was obtained after the nature and possible conse-
quences of the study were explained. Participants inserted the device into
the vagina for at least 30 s, removed it, and placed it into a 50-ml centrifuge
tube. Samples were centrifuged at 230 	 g for 2 min to collect the secre-
tions. Samples were collected at random times with respect to the men-
strual cycle, and cycle phase was estimated based on the last menstrual
period date normalized to a 28-day cycle. While a woman’s vaginal mi-
crobiota may vary throughout the menstrual cycle (9, 23), to avoid poten-
tial biases due to menstrual cycle effects, no participant was sampled more
than once in this study. No samples were ovulatory as judged on the basis
of visual observation (none exhibited “spinnbarkeit” [spinnability]).
Samples that were nonuniform in color or consistency were discarded.
Donors stated they had not used vaginal products or participated in un-
protected intercourse within 3 days prior to donating and indicated
whether they had participated in protected intercourse within 24 h prior
to donating. Donors also reported whether they had been using a hor-
monal contraceptive in the 3 weeks prior to donating. No donors reported
having had STIs or other vaginal conditions within 7 days prior to donat-
ing. HIV-1 mobility in CVM did not correlate with donor age, race, con-
traceptive use, or menstrual cycle phase (see Table S1).
The pH of CVM samples was measured immediately after sample
collection using a pH microelectrode (Microelectrodes, Inc., Bedford,
NH) calibrated to pH 4, 7, and 10 buffers. Vaginal smear slides for Gram
staining and aliquots of CVM for lactic acid measurements (diluted 1:5
with 1	 PBS and stored at 80°C) were also prepared immediately, and
the remainder of the sample was stored at 4°C until microscopy, typically
within a few hours. Gram-stained slides were viewed under a 100	 ob-
jective, and Nugent scores were calculated following scoring criteria de-
scribed previously (7). For lactic acid measurements, CVM aliquots were
thawed and centrifuged for 2 min at 21,130 	 g to obtain cell-free super-
natant containing lactic acid, which was measured using a D/L-lactic acid
kit (R-Biopharm, Darmstadt, Germany) following the manufacturer pro-
tocol adapted to a 96-well format.
Multiple-particle tracking of HIV-1 and nanoparticles in CVM. Flu-
orescent virions or beads (approximately 108 to 109 particles/ml) were
added at 5% (vol/vol) to 20 l of CVM placed in a custom-made glass
chamber and incubated for 1 h at 37°C prior to microscopy. In a subset of
samples, an aliquot of CVM was first titrated to pH 6.8 to 7.1 using small
volumes (~3% [vol/vol]) of 3 N NaOH to mimic neutralization of CVM
by alkaline seminal fluid. The translational motions of the particles were
recorded using an electron multiplying charge-coupled-device (EMCCD)
camera (Evolve 512; Photometrics, Tucson, AZ) mounted on an inverted
epifluorescence microscope (AxioObserver D1; Zeiss, Thornwood, NY)
equipped with an Alpha Plan-Apo 100	/1.46 numerical-aperture (NA)
objective, an environmental (temperature and CO2)-control chamber,
and a light-emitting-diode (LED) light source (Lumencor Light Engine
DAPI/GFP/543/623/690). Videos (512 pixels by 512 pixels, 16-bit image
depth) were captured with MetaMorph imaging software (Molecular De-
vices, Sunnyvale, CA) at a temporal resolution of 66.7 ms and a spatial
resolution of 10 nm (nominal pixel resolution, 0.156 m/pixel) for 20 s.
The tracking resolution was determined by tracking the displacements of
particles immobilized with a strong adhesive, following a previously de-
scribed method (45). Particle trajectories (xy locations) were obtained
using MatLab software, following methods originally developed in IDL by
Crocker and Hoffman (46). Subpixel tracking resolution was achieved by
determining the precise location of particle centroids by light-intensity-
weighed averaging of neighboring pixels. Trajectories were analyzed using
a frame-by-frame approach (Y.-Y. Wang, K. L. Nunn, D. Harit, S. A.
McKinley, and S. K. Lai, submitted for publication) in which mean
squared displacements (MSD) and effective diffusivities (Deff) are first
calculated for individual particle traces, as previously described (11, 18,
44), and averages and distributions are then calculated at each frame based
on only the particles present in that frame before averaging across all
frames in the movie. This approach minimizes bias toward faster-moving
particle subpopulations due to the particles potentially moving into and
out of the focal plane multiple times throughout the course of a movie
(this results in multiple traces, whereas only a single trace is typically
recorded for a trapped particle). Trajectories of 40 particles per frame
on average were analyzed for each experiment, which typically corre-
sponds to 100 individual particle traces throughout the video and is
consistent with the extent of sampling in our previous work (Wang et al.,
submitted). Trapped particles were defined by a Deff value of
101.5 m2/s at a  value of 0.2667 s (time scale corresponding to a
minimum trajectory length of 5 frames); for particles 200 nm in diameter
and larger, this cutoff translates to particles moving a distance that is
much less than their diameter within 0.2667 s.
16S rRNA sequencing and analysis. DNA extractions for microbiome
analysis were performed using previously described protocols (23) on
aliquots of the same CVM samples used for microscopy studies and other
characterizations described above. The detailed method of Fadrosh et al.
(47) was used to analyze the vaginal microbiota composition and struc-
ture and relied on amplification and sequencing on an Illumina MiSeq
instrument (300-bp paired-end reads) of the V3-to-V4 region of the 16S
rRNA gene. Sequence analyses and taxonomic assignments were per-
formed using a custom pipeline, freely available on GitHub (https://
github.com/cwzkevin/MiSeq16S). The resulting taxonomic assignments
are shown in Table S2 in the supplemental material. To assess whether the
vaginal microbiota affects the barrier properties of CVM, we first grouped
any CVM samples with an appreciable (5%) abundance of G. vaginalis
(group 3), since G. vaginalis is thought to potentially increase the risks of
HIV transmission by secreting sialidases and other enzymes that degrade
mucins (21, 32). Thus, any CVM specimens with appreciable quantities of
G. vaginalis, even at relatively low levels, are likely to have had their barrier
properties compromised to some extent. We next grouped the remaining
CVM specimens based on whether they were L. crispatus-dominant
(group 1) or L. iners-dominant (group 2) to determine whether L. crispa-
tus and L. iners have differential effects on CVM barrier properties.
Statistical analysis. Statistical comparisons were limited to two
groups (CVM samples that trapped HIV-1 versus those that did not trap
HIV-1 and CVM samples with microbiota dominated by L. crispatus ver-
sus those dominated by L. iners or containing substantial G. vaginalis). A
one-tailed Student’s t test, assuming unequal variances, was used for all
comparisons. Differences were deemed significant at an alpha level of
0.05. All values are reported as means  SEM unless otherwise indicated.
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